Marpai, Inc.: insider trades · United States · SEC (Form 4)

About Marpai, Inc.

Marpai, Inc. is a U.S.-based healthcare services and technology company headquartered in Tampa, Florida, United States. The shares were formerly listed on the Nasdaq Capital Market under the ticker MRAI before the company transitioned trading to the OTCQX market. For investors, Marpai is best understood as a small-cap healthcare administration platform focused on self-funded employer health plans, with an operating model built around technology-enabled benefits administration and adjacent pharmacy services. At the core of Marpai’s business is Third-Party Administration (TPA) for self-insured employers. Through its subsidiaries, the company provides back-office administration for health and welfare plans, including claims administration, dependent eligibility verification, COBRA administration, benefit billing, and related call-center support. The company emphasizes that these services are supported by a customized technology platform. Marpai also highlights the use of artificial intelligence to identify at-risk members earlier, connect them with clinical solutions, and guide them toward lower-cost, in-network providers. In practical terms, the company is selling a combination of administrative outsourcing, analytics, and care-navigation tools designed to help employers manage healthcare spend. Marpai’s corporate history reflects a relatively recent formation and a continuing strategic reset. Public filings indicate that Marpai Captive was founded in March 2022 as a Delaware corporation, underscoring the company’s effort to broaden its ecosystem beyond traditional TPA work. More recently, Marpai has expanded its footprint with MarpaiRx, its pharmacy benefit management initiative. That move is strategically important because PBM capabilities can deepen client relationships, increase recurring revenue potential, and provide another lever for cost containment in employer-sponsored healthcare. Competitive positioning is a key consideration. Marpai operates in a large but highly competitive and fragmented market where scale matters, and where larger national administrators and benefit managers often enjoy stronger purchasing power, broader networks, and more established distribution. Marpai’s differentiation is therefore more niche than universal: it targets self-funded employers, promotes a technology-led operating model, and seeks to win business through smarter claims administration and cost-optimization rather than through sheer size. The company’s competitive edge depends on execution, customer acquisition, and its ability to translate technology claims into measurable client savings. Recent developments point to an improving operating narrative. In May 2026, Marpai announced significant new business wins across both TPA and MarpaiRx and said those wins reinforce its profitability outlook. In March 2026, it also disclosed a marketing arrangement intended to expand the reach of MarpaiRx. Across its latest communications, management has stressed cost discipline, operational improvement, and a path toward profitability. For market participants, Marpai remains a turnaround story rather than a mature healthcare incumbent, but one with a clear strategic focus and identifiable catalysts in the U.S. market.